Ropes & Gray represented Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases in an upsized concurrent registered offering of $225 million of 1.75% convertible notes due 2032 and $125 million of common stock at a public offering price of $17 per share. The offering priced on May 6 and closed on May 11.
Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for validated drug targets and disease-driving mechanisms in autoimmune and rare diseases.
The team was led by capital markets partner Tristan VanDeventer and included capital markets partner Zach Blume and counsel Lisa Folkerth and tax partner David Saltzman.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.